



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Technically
Speaking

CEDARLANE[®]
www.cedarlanelabs.com



Conveniently Delivering You Today's Innovations
for the Science of Tomorrow™

Purified Mouse Anti-HIV Protease Monoclonal Antibody

CLX160AP

Lot:

Size: 0.1 mg

Clone: 1696

Isotype: Mouse IgG1

Specificity: The antibody 1696 recognizes free N-terminus of mature HIV protease (HIV-1 and HIV-2), an enzyme that hydrolyzes polyproteins of HIV viruses into functional proteins. The antibody 1696 does not react with the precursor.

Application: **Western Blotting**
Recommended dilution: 0.5 µg/ml
Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with reducing Laemmli SDS-PAGE sample buffer. Application note: Reducing conditions.

ELISA

Functional Application

The antibody 1696 strongly inhibits the enzyme activity of HIV-1 and HIV-2 proteases.

Purity: > 95% (by SDS-PAGE)

Purification: Purified from ascites by protein-A affinity chromatography.

Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage / Stability: Store at 2-8°C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20°C. Avoid freeze/thaw cycles.

Continued...

Visit our website for your local distributor.

CEDARLANE[®]



www.cedarlanelabs.com

An ISO 9001:2000 and ISO 13485:2003
registered company.

In CANADA: Toll Free: 1-800-268-5058

4410 Paletta Court, Burlington, ON L7L 5R2 ph: (289) 288-0001, fax: (289) 288-0020
e-mail: general@cedarlanelabs.com

In the USA: Toll Free: 1-800-721-1644

1210 Turrentine Street, Burlington, NC 27215 ph: (336) 513-5135, fax: (336) 513-5138
e-mail: service@cedarlanelabs.com

Background:

The HIV protease (PR) hydrolyzes polyproteins of HIV virus into functional protein products that are essential for its assembly and subsequent activity. This maturation process occurs as the virion buds from the host cell. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. HIV protease inhibitors can lower the viral load carried by AIDS patients.

References:

- *Velazquez-Campoy A, Todd MJ, Vega S, Freire E.: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7.
- *Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber I.T.: Caught in the Act: the 1.5 Å resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 25;46(51):14854-64.
- *Brower ET, Bacha UM, Kawasaki Y, Freire E.: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr;71(4):298-305.
- *Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg J.E.: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 10;9(1):181
- *Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley G.A.: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec;8(12):2686-96.
- *O'Loughlin TL, Greene DN, Matsumura I.: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr;23(4):764-72.
- *Bartonová V, Král V, Siegllová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedláček J, Rezacová P.: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun;78(3):275-7. Epub 2008 Feb 20.

Laboratory Reagent For Research Use Only